Multitarget stool DNA test (Cologuard ... ability to find a cancer if it's there. Keep in mind that these figures are based on two-step testing of positive results — if the home test finds ...

1* Results from BLUE-C also show the Cologuard Plus test significantly outperformed ... sensitivity than Cologuard while reducing false positives by more than 30 percent. This breakthrough comes ...

Study participants (N=20,176) provided stool samples that were then tested with both Cologuard Plus and FIT; colonoscopy results ... of false positives. This makes the Cologuard Plus test a ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential colon cancer or polyps. It’s popular due to its noninvasive nature and ...

Let’s start with the cheapest, the yearly FIT, or fecal immunochemical test, which looks for fecal blood that might be caused ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Recommended Reading Exact Sciences says data support ...

4-5) Exact refers to its Cologuard cancer screening test ... and hemoglobin results are combined in the laboratory analysis through a proprietary algorithm to provide a single positive or negative ...

(1) Interest expense includes net gains recorded of $10.3 million and $10.3 million for the nine months ended September 30, 2024 and September 30, 2023, respectively, from the settlement of ...

At this time, I would like to welcome everyone to the Exact Sciences third-quarter 2024 earnings conference call. [Operator ...

Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A and ...

There were no acquisition costs incurred for ... to the Company’s Oncotype DX Genomic Prostate Score® (“GPS”) test to MDxHealth SA (“MDxHealth”) in August 2022 and the subsequent ...